Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer

Inclusion Criteria

• •1. Eastern Cooperative Oncology Group (ECOG) Performance Status≤2 or Karnofsky performance statu (KPS) scores≥60.
• •2. Patients with cytologically or histologically confirmed lung cancer.
• •3. Patients who are willing to receive chemotherapy and can tolerate at least 2 cycles chemotherapy.
• •4. Chemotherapy regimens accord with standard regimens recommended by clinical practice guidelines (National Comprehensive Cancer Network guidelines and Chinese Society of Clinical Oncology guidelines of lung cancer).
• •5. There is at least one kind of high emetic risk chemotherapy agent, mainly including regimens contain cisplatin or carboplatin (AUC≥4).
• •6. Adequate organ function including the following: Adequate bone marrow reserve: white blood cell (WBC) count superior or equal to 2.0×10\^9/L , absolute neutrophil count (ANC) superior or equal to 1.5×10\^9/L, platelets superior or equal to 80×10\^9/L, and hemoglobin superior or equal to 90g/L; Hepatic: bilirubin \<1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5×ULN (or \<5×ULN with liver metastases); Renal: Serum creatinine≤1×ULN, calculated creatinine clearance (CrCl) superior or equal to 50 milliliter/min based on the standard Cockcroft and Gault formula.
• •7. At least 3 weeks after the end of the last chemotherapy.
• •8. Women of reproductive years are willing to contracept in appropriate methods in the period of trial and in the 8 weeks after the last administration. Doing pregnancy test before the beginning of this trial when necessary, and results of which need to be negative.